Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - PRECISION BIOSCIENCES INC | dtil-ex321_171.htm |
EX-31.2 - EX-31.2 - PRECISION BIOSCIENCES INC | dtil-ex312_173.htm |
EX-31.1 - EX-31.1 - PRECISION BIOSCIENCES INC | dtil-ex311_170.htm |
EX-10.5 - EX-10.5 - PRECISION BIOSCIENCES INC | dtil-ex105_291.htm |
EX-10.4 - EX-10.4 - PRECISION BIOSCIENCES INC | dtil-ex104_317.htm |
EX-10.3 - EX-10.3 - PRECISION BIOSCIENCES INC | dtil-ex103_117.htm |
EX-10.2 - EX-10.2 - PRECISION BIOSCIENCES INC | dtil-ex102_118.htm |
EX-10.1 - EX-10.1 - PRECISION BIOSCIENCES INC | dtil-ex101_169.htm |
10-Q - Q1'21 10-Q - PRECISION BIOSCIENCES INC | dtil-10q_20210331.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Precision BioSciences, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 13, 2021 |
|
By: |
/s/ John Alexander Kelly |
|
|
|
John Alexander Kelly |
|
|
|
Interim Chief Financial Officer |
|
|
|
(principal financial officer) |